Ratings by Craig-Hallum (John Wilkin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/14/2026 | MDxHealth SA | MDXH | Maintain | Buy (N/A) |
|
Details | ||
| 5/6/2026 | Myriad Genetics | MYGN | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2026 | Exagen | XGN | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2026 | Adeptus Biotechnologies Corp. | ADPT | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2025 | Adeptus Biotechnologies Corp. | ADPT | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2025 | Personalis | PSNL | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2025 | Personalis | PSNL | Maintain | Buy (N/A) |
|
Details | ||
| 7/23/2025 | Exagen | XGN | New Coverage | Buy (N/A) |
6.94 (4.14) |
-40.35% | Details | |
| 7/17/2025 | MDxHealth SA | MDXH | New Coverage | Buy (N/A) |
2.20 (0.43) |
-80.45% | Details | |
| 6/18/2025 | Adeptus Biotechnologies Corp. | ADPT | New Coverage | Buy (N/A) |
10.14 (21.02) |
107.3% | Details | |
| 5/7/2025 | Myriad Genetics | MYGN | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2025 | Veracyte, Inc | VCYT | New Coverage | Buy (N/A) |
31.78 (57.48) |
80.87% | Details | |
| 3/17/2025 | Personalis | PSNL | New Coverage | Buy (N/A) |
3.63 (15.04) |
314.33% | Details | |
| 2/12/2025 | Myriad Genetics | MYGN | New Coverage | Buy (N/A) |
12.57 (5.86) |
-53.38% | Details |
